<h1>Tariff on branded pharmaceuticals exempted if US manufacturing is under construction, so generic exporters expect limited impact.</h1> A US trade measure imposes a 100 percent tariff on branded and patented pharmaceutical products unless the company is 'is building' a manufacturing plant in the United States, where 'is building' is defined as breaking ground or under construction; Indian exporters expect little impact because principal shipments to the US are generic medicines rather than patented branded drugs.